Unlock instant, AI-driven research and patent intelligence for your innovation.

A peripheral blood biomarker for the diagnosis of first-episode schizophrenia

A technology for schizophrenia and peripheral blood, applied in disease diagnosis, biological testing, biomaterial analysis, etc., can solve problems such as misdiagnosis, low sensitivity and accuracy of schizophrenia detection, and impact on patients' confidence in treatment, doctor's hospital trust, etc.

Inactive Publication Date: 2019-06-07
BEIJING ANDING HOSPITAL CAPITAL MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Misdiagnosis will lead to patients not receiving effective treatment, and will also greatly damage patients' confidence in treatment and trust in doctors and hospitals, reduce compliance, and further cause various serious consequences. Therefore, it is urgent to treat schizophrenia and the above two diseases. differential diagnosis
[0006] At present, the detection sensitivity and accuracy of biomarkers for schizophrenia are not high, and there is no detection method that can distinguish schizophrenia from bipolar disorder and depression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A peripheral blood biomarker for the diagnosis of first-episode schizophrenia
  • A peripheral blood biomarker for the diagnosis of first-episode schizophrenia
  • A peripheral blood biomarker for the diagnosis of first-episode schizophrenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Example 1: Diagnosis of first-episode schizophrenia and determination of severity of first-episode schizophrenia

[0075] The sera of the schizophrenia population, ultra-high-risk population and healthy control population were collected, and the concentration of soluble IL-15Rα in the serum was detected with a commercially available soluble IL-15Rα ELISA kit. Statistical differences among different groups were judged by t test. The result is as figure 1 As shown in , the concentration of soluble IL15Rα in patients with first-episode schizophrenia is the lowest, and there is a very significant difference with the healthy control group, while the ultra-high-risk group is between normal people and patients, showing a good dose-effect relationship. The results indicate that the detection of soluble IL15Rα concentration can be used to diagnose the first-episode schizophrenia and determine the severity of the first-episode schizophrenia.

Embodiment 2

[0076] Example 2: Diagnosis of first-episode schizophrenia and differential diagnosis between first-episode schizophrenia and bipolar disorder

[0077] The serum of first-episode schizophrenia group, bipolar disorder group and healthy control group was collected, and the concentration of soluble IL-15Rα in serum was detected with a commercially available soluble IL-15Rα ELISA kit. Statistical differences among different groups were judged by t test. The result is as figure 2 As shown in , patients with first-episode schizophrenia had the lowest concentrations of soluble IL15Rα and were highly significantly different from healthy controls, while those with bipolar disorder had similar concentrations of soluble IL15Rα to patients with first-episode schizophrenia difference. The results indicate that the detection of soluble IL15Rα concentration can be used for the diagnosis of first-episode schizophrenia and the differential diagnosis between first-episode schizophrenia and b...

Embodiment 3

[0078] Example 3: Diagnosis of first-episode schizophrenia and differential diagnosis between first-episode schizophrenia and depression

[0079] The serum of first-episode schizophrenia group, depression group and healthy control group was collected, and the concentration of soluble IL-15Rα in serum was detected with a commercially available soluble IL-15Rα ELISA kit. Statistical differences among different groups were judged by t test. The result is as figure 2As shown in , first-episode schizophrenia patients had the lowest soluble IL15Rα concentration, which was highly significantly different from healthy controls, while the depressed population was similar to healthy controls but significantly different from first-episode schizophrenia patients. The results indicated that the detection of soluble IL15Rα concentration can be used for the diagnosis of first-episode schizophrenia and the differential diagnosis between first-episode schizophrenia and depression.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a peripheral blood biomarker used for first-episode schizophrenia diagnosis and application of the biomarker for diagnosing first-episode schizophrenia. Particularly, a first-episode schizophrenia patient is diagnosed by detecting the level of free IL-15Ralpha in peripheral blood.

Description

technical field [0001] The disclosure relates to objective diagnosis of mental illness, diagnosis of schizophrenia course severity, differential diagnosis of first-episode schizophrenia and bipolar disorder, objective biomarkers, and peripheral blood biomarkers. Background technique [0002] Schizophrenia is a common mental illness with a prevalence rate of 0.3%-0.7% in the global population. Schizophrenia usually occurs in young and middle-aged adults, and there are often obstacles in perception, thinking, emotion, and behavior, as well as incoordination of mental activities, which seriously affect the patient's physical function and quality of life. While some patients recover with treatment, most suffer from recurrent episodes over a long period of time, making schizophrenia not only an individual disease but also a serious social problem with consequences for families, the health care system and society at large obvious financial burden. [0003] At present, the clinic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2800/302
Inventor 贺毅王传跃孙作厘
Owner BEIJING ANDING HOSPITAL CAPITAL MEDICAL UNIV